Profile data is unavailable for this security.
About the company
NeutriSci International Inc. (NeutriSci) is a Canada-based company, which specializes in the development, formulation, and production of products for its business-to-business (B2B) partners around the globe. The Company is focused on the market development for its nutraceutical products. Its products utilize patented form of Pterostilbene called pTeroPure. pTeroPure Pterostilbene is a form of all-trans Pterostilbene that is found naturally in blueberries and is manufactured for NeutriSci by ChromaDex Corp. (ChromaDex) in the United States. NeutriSci’s neuenergy product is an energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash that is associated with energy products. It has developed proprietary IP and technology (NeutriSci IP) that creates an efficient method of bilingual absorption of nutraceuticals into the bloodstream. NeutriSci’s IP can be applied to many different categories in the beverage, food, and nutraceutical space.
- Revenue in CAD (TTM)59.98k
- Net income in CAD-552.46k
- Incorporated2014
- Employees--
- LocationNeutriSci International Inc1600 - 609 Granville StVANCOUVER V7Y 1C3CanadaCAN
- Phone+1 (778) 331-8505
- Fax+1 (778) 331-8505
- Websitehttps://neutrisci.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zenith Capital Corp | 0.00 | -23.10m | 775.99k | -- | -- | -- | -- | -- | -0.1577 | -0.1577 | 0.00 | -0.1702 | 0.00 | -- | -- | -- | -339.76 | -- | -- | -- | -- | -- | -- | -- | -- | -9.97 | -- | -- | -- | -- | -68.27 | -- | -- | -- |
| Psybio Therapeutics Corp | 0.00 | -3.86m | 839.27k | 4.00 | -- | -- | -- | -- | -0.0331 | -0.0331 | 0.00 | -0.0181 | 0.00 | -- | -- | -- | -357.70 | -- | -- | -- | -- | -- | -- | -- | -- | -617.30 | -- | -- | -- | -- | 55.66 | -- | -- | -- |
| Lumiera Health Inc | 592.62k | -2.36m | 845.13k | -- | -- | -- | -- | 1.43 | -0.0139 | -0.0139 | 0.0035 | -0.0136 | 0.5096 | 2.13 | 11.78 | -- | -202.92 | -- | -- | -- | 13.17 | -- | -398.18 | -- | 0.0395 | -2.10 | -- | -- | 46.91 | -- | -188.58 | -- | -- | -- |
| NeutriSci International Inc | 59.98k | -552.46k | 892.12k | -- | -- | -- | -- | 14.87 | -0.0032 | -0.0032 | 0.0003 | -0.0051 | 0.2988 | 1.33 | 11.47 | -- | -275.23 | -288.65 | -- | -- | -43.90 | -7.95 | -921.07 | -1,046.33 | 0.0059 | -- | -- | -- | 465.89 | 24.82 | 50.98 | -- | -- | -- |
| Claritas Pharmaceuticals Inc | 0.00 | -2.62m | 957.26k | -- | -- | -- | -- | -- | -0.0852 | -0.2039 | 0.00 | 0.1267 | 0.00 | -- | -- | -- | -17.49 | -33.39 | -51.79 | -39.16 | -- | -- | -- | -- | -- | 6.86 | 0.1409 | -- | -- | -- | 119.85 | -- | -- | -- |
| Hill Inc | 2.22m | -1.97m | 1.02m | -- | -- | 1.44 | -- | 0.4587 | -0.6076 | -0.6076 | 0.6822 | 0.2159 | 0.5046 | 129.23 | 4.56 | -- | -44.92 | -77.46 | -48.92 | -101.03 | 68.14 | 50.14 | -89.01 | -153.93 | 2.97 | -4.23 | 0.7881 | -- | -10.23 | 33.86 | 18.26 | -- | 16.21 | -- |
